ZOETIS INC CLASS A (ZTS)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for ZTS
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ZTS | Chief Executive Officer of Zoetis Inc.; Chief Executive Officer (“CEO”) | 54 | ["More than 25 years in business management","20-plus years in the health care and animal health industry","Knowledge of Zoetis since its initial public offering in 2013","Experience in development, implementation and execution of corporate strategy","Strong business experience as Chief Executive Officer"] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| BLK | CEO of Zoetis, Inc.; Chief Executive Officer; Member | 54 | ["Senior Executive & Corporate Governance","Branding & Marketing","Global Business","Public Company & Financial Reporting","Public Policy & Government/Regulatory Affairs"] | ["MD","CC","NGC","Nominating & Governance Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Chief Executive Officer of Zoetis Director since: October 2019 Committees: None Age: 54 Other Current Public Company Directorships: BlackRock (since September 2021) Deep expertise in animal health, having paved the way for Zoetis as a public company and defining a global sector. Broad leadership experience spanning Zoetis Global Manufacturing and Supply, Global Commercial Development, and its $2.9 billion U.S. Commercial Business groups. Extensive experience in finance and innovation across several companies. Since becoming CEO of Zoetis in 2020, Ms. Peck delivered superior financial growth and industry-leading operating margins; launched 18 blockbuster products and established a pipeline of 12 more potential blockbusters (products with expected future potential annual sales of $100M+). Strategic and innovative leader with experience in corporate strategy, business development, and digital transformation including the acceleration of AI adoption and advanced analytics which has been central to Zoetis sustained growth and innovation since its IPO. Passion and commitment to life sciences and healthcare. Proven leadership in public policy and advocacy as past president of the Animal Health Institute and HealthforAnimals. Currently serves on the Board of Trustees of the Mayo Clinic, a top-ranked global medical center. Recognized for her transformative leadership in driving Zoetis strong performance and innovation, Ms. Peck was named to TIME100 Most Influential People in Health for 2025; included on the CNBC 2024 Changemakers list; selected by Barron s as one of the top CEOs in 2022 and honored by Fortune as a 2020 Businessperson of the Year. Ms. Peck is a member of the board of directors of Business Roundtable (since January 2026). She previously served as a member of the board of directors of Thomson Reuters. Career Highlights: Zoetis Inc. (NYSE: ZTS) a leading global producer of medicine and vaccinations for pets and livestock Chief Executive Officer (2020-present) Executive Vice President and Group President, U.S. Operations, Business Development and Strategy (2018-2019) Executive Vice President and President, U.S. Operations (2015-2018) Pfizer Inc. (NYSE: PFE) a global pharmaceutical company Executive Vice President, Worldwide Business Development and Innovation (2004-2012) Education: Bachelor s degree from Georgetown University Master of Business Administration from Columbia Business School